Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberta Chapman

Cardiovascular Disease Gloucester, VA Medical Doctor

NPI 1942266168 CMS profile 315123

6031 Industrial Dr, Ste 400, Gloucester, VA 23061

Open in the dashboard

General payments

$154,635

186 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$185,725 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Roberta Chapman of Gloucester, VA is reported in the CMS Open Payments database as having received $154,635 across 186 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $185,725 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $253 3
2022 General $513 4
2020 General $53,832 65
2019 General $100,037 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberta Chapman
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Roberta Chapman were reported at $253. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Roberta Chapman Cardiovascular Disease median Middle half National median
2019 $100,037 $450 $127–$1,392 $163
2020 $53,832 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $513 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $253 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $72,569 53 payments
  2. AstraZeneca Pharmaceuticals LP $27,156 30 payments
  3. Abiomed $23,989 20 payments
  4. Amgen Inc. $16,065 20 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10,280 25 payments
  6. Abbott Laboratories $2,726 27 payments
  7. Pfizer Inc. $1,590 2 payments
  8. Relypsa, Inc. $155 3 payments
  9. Alnylam Pharmaceuticals Inc. $28 2 payments
  10. Medtronic Vascular, Inc. $21 1 payment
  11. Other $56 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84,570 47 payments
  2. Honoraria $23,550 7 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $20,632 3 payments
  4. Travel and Lodging $12,040 31 payments
  5. Consulting Fee $8,605 3 payments
  6. Food and Beverage $5,238 95 payments
Products named General payments · program years 2019–2025
  1. ENTRESTO $72,569 53 payments
  2. FARXIGA $27,097 27 payments
  3. Impella $23,989 20 payments
  4. Repatha $16,065 20 payments
  5. LifeVest $10,280 25 payments
  6. VYNDAQEL $1,590 2 payments
  7. HeartMate 3 Left Ventricular Dev $970 12 payments
  8. CardioMEMS HF System $768 6 payments
  9. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $513 4 payments
  10. CARDIOMEMS $253 3 payments
  11. Other $541 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record